Skip to main content
Premium Trial:

Request an Annual Quote

International Genomics Consortium Names Michael Berens as CEO

NEW YORK, March 21 -- Michael Berens, a researcher at Arizona's Translational Genomics Research Institute, has become CEO of the International Genomics Consortium, the IGC said today.

 

His first task will be to talk to potential partners, such as pharmaceutical companies, and to raise funds for the consortium, according to an IGC spokesperson.

 

Berens, a former researcher at the Barrow Neurological Institute, will keep his position as senior investigator at the Translational Genomics Research Institute in order to be able to pursue federally funded research.

 

Further, the Phoenix, Ariz.-based consortium named Robert Penny as chief medical officer, Michael Bittner as chief research officer, and Michael Rodgers as chief financial officer. In addition, Max Poll, president and CEO at Scottsdale Healthcare, was elected to the IGC's board.

 

The IGC, a non-profit medical research foundation, is planning to collect tissue samples from a variety of sources and analyze them using genomics technologies. Its first project will be to study gene expression in cancer.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.